List of SBIR/STTR awards granted to Thetis Pharmaceuticals (company)
Thetis Pharmaceuticals (company)Name | Description | SBIR/STTR Award Recipient | Government Agency | Government Branch | Award Type | Contract Number (US Government) | Award Phase | Award Amount (USD) | Date Awarded | Official Website | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
A SBIR Phase II contract was awarded to Thetis Pharmaceuticals (company) in May, 2019 for $1,196,452.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health. | SBIR | 4R44DK116463-02 | Phase II | 1,196,452 | May 1, 2019 | |||||||
A SBIR Phase I contract was awarded to Thetis Pharmaceuticals (company) in June, 2018 for $205,144.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health. | SBIR | 1R44DK116463-01A1 | Phase I | 205,144 | June 1, 2018 | |||||||
A SBIR Phase I contract was awarded to Thetis Pharmaceuticals (company) in August, 2021 for $299,561.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health. | SBIR | 1R44AI157697-01A1 | Phase I | 299,561 | August 6, 2021 | |||||||
A SBIR Phase II contract was awarded to Thetis Pharmaceuticals (company) in March, 2020 for $1,982,861.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health. | SBIR | 4R44DK121612-02 | Phase II | 1,982,861 | March 1, 2020 | |||||||
A SBIR Phase I contract was awarded to Thetis Pharmaceuticals (company) in September, 2019 for $295,609.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health. | SBIR | 1R44DK121612-01A1 | Phase I | 295,609 | September 1, 2019 | |||||||
A SBIR Phase I contract was awarded to Thetis Pharmaceuticals (company) in September, 2017 for $205,992.0 USD from the U.S. Department of Health & Human Services. | SBIR | 1R44DK116460-01 | Phase I | 205,992 | September 18, 2017 | |||||||
A SBIR Phase I contract was awarded to Thetis Pharmaceuticals (company) in June, 2023 for $398,404.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health. | SBIR | 1R44CA278026-01A1 | Phase I | 398,404 | June 2, 2023 | |||||||
A SBIR Phase II contract was awarded to Thetis Pharmaceuticals (company) in March, 2023 for $997,635.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health. | SBIR | 2R44DK116460-04 | Phase II | 997,635 | March 15, 2023 |
